Impact of immune response on the use of iPSCs in disease modeling

Current Stem Cell Research and Therapy

Volumn 10, Issue 3, 2015, Pages 236-244

  Zhang, Zimu ^a   Huang, Biao ^a   Gao, Fei ^b   Zhang, Rongxin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF ZOOLOGY   (China)

Author keywords

Disease modeling; Immune response; Immunogenicity; Induced multipotent progenitor cells; Induced pluripotent stem cells; Reprogramming

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FAS LIGAND; HLA ANTIGEN; INTERLEUKIN 6; KRUPPEL LIKE FACTOR 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MYC PROTEIN; MYCOPHENOLATE MOFETIL; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; TAPASIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA2; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

ADAPTIVE IMMUNITY; ADENOSINE DEAMINASE DEFICIENCY; ALZHEIMER DISEASE; ARTICLE; BECKER MUSCULAR DYSTROPHY; CELL DIFFERENTIATION; DISEASE MODEL; DOWN SYNDROME; DUCHENNE MUSCULAR DYSTROPHY; EPIGENETICS; HEART MUSCLE ISCHEMIA; HUMAN; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LESCH NYHAN SYNDROME; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NATURAL KILLER CELL; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; ANIMAL; CELLULAR IMMUNITY; CYTOLOGY; IMMUNOLOGY; MOUSE; NUCLEAR REPROGRAMMING; STEM CELL TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELLULAR REPROGRAMMING; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, CELLULAR; INDUCED PLURIPOTENT STEM CELLS; MICE; STEM CELL TRANSPLANTATION;

EID: 84928945854     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X09666140711120449     Document Type: Article

References (76)

1. Callihan P, Mumaw J, Machacek DW, et al.Regulation of stem cell pluripotency and differentiation by G protein coupled receptors. Pharmacol Ther 2011; 129(3): 290-306.
2. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al.Embryonic stem cell lines derived from human blastocysts. Science 1998; 282(5391): 1145-7.
3. Tachibana M, Amato P, Sparman M, et al.Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013; 153(6): 1228-38.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-76.
5. Zhao T, Zhang Z-N, Rong Z, et al.Immunogenicity of induced pluripotent stem cells. Nature 2011; 474(7350): 212-5.
6. Araki R, Uda M, Hoki Y, et al.Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494(7435): 100-4.
7. Guha P, Morgan JW, Mostoslavsky G, et al.Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013; 12(4): 407-12.
8. Morizane A, Doi D, Kikuchi T, et al.Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Reports 2013; 1(4): 283-92.
9. Takahashi K, Tanabe K, Ohnuki M, et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-72.
10. Yu J, Vodyanik MA, Smuga-Otto K, et al.Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-20.
11. Nakagawa M, Koyanagi M, Tanabe K, et al.Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26(1): 101-6.
12. Eminli S, Utikal J, Arnold K, et al.Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 2008; 26(10): 2467-74.
13. Aoi T, Yae K, Nakagawa M, et al.Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321(5889): 699-702.
14. Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic cells into induced pluripotent stem cells. Curr Biol 2008; 18(12): 890-4.
15. Ebert AD, Yu J, Rose FF, et al.Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457(7227): 277-80.
16. Aasen T, Raya A, Barrero MJ, et al.Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26(11): 1276-84.
17. Staerk J, Dawlaty MM, Gao Q, et al.Reprogramming of peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 2010; 7(1): 20-4.
18. Liu H, Ye Z, Kim Y, et al.Generation of endoderm‐derived human induced pluripotent stem cells from primary hepatocytes. Hepatology 2010; 51(5): 1810-9.
19. Zhou T, Benda C, Dunzinger S, et al.Generation of human induced pluripotent stem cells from urine samples. Nat Protoc 2012; 7(12): 2080-9.
20. Buchholz DE, Hikita ST, Rowland TJ, et al.Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 2009; 27(10): 2427-34.
21. Senju S, Haruta M, Matsumura K, et al.Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. Gene Ther 2011; 18(9): 874-83.
22. Itzhaki I, Maizels L, Huber I, et al.Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011; 471(7337): 225-9.
23. Israel MA, Yuan SH, Bardy C, et al.Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012; 482(7384): 216-20.
24. Firth AL, Dargitz CT, Qualls SJ, et al.Generation of multiciliated cells in functional airway epithelia from human induced pluripotent stem cells. Proc Natl Acad Sci USA 2014; 111(17): E1723-30.
25. Park I-H, Arora N, Huo H, et al.Disease-specific induced pluripotent stem cells. Cell 2008; 134(5): 877-86.
26. Stadtfeld M, Nagaya M, Utikal J, et al.Induced pluripotent stem cells generated without viral integration. Science 2008; 322(5903): 945-9.
27. Okita K, Nakagawa M, Hyenjong H, et al.Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322(5903): 949-53.
28. Kaji K, Norrby K, Paca A, et al.Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458(7239): 771-5.
29. Kim D, Kim C-H, Moon J-I, et al.Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4(6): 472-6.
30. Warren L, Manos PD, Ahfeldt T, et al.Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-30.
31. Hou P, Li Y, Zhang X, et al.Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341(6146): 651-4.
32. Huangfu D, Maehr R, Guo W, et al.Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26(7): 795-7.
33. Maherali N, Hochedlinger K. Tgf signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr Biol 2009; 19(20): 1718-23.
34. Kawamura T, Suzuki J, Wang YV, et al.Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460(7259): 1140-4.
35. Esteban MA, Wang T, Qin B, et al.Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010; 6(1): 71-9.
36. Wang Y, Tian C, Zheng JC. FoxO3a Contributes to the Reprogramming Process and the Differentiation of Induced Pluripotent Stem Cells. Stem Cells Dev 2013; 22(22): 2954-63.
37. Parchem RJ, Ye J, Judson RL, et al.Two miRNA Clusters Reveal Alternative Paths in Late-Stage Reprogramming. Cell Stem Cell 2014; 14(5): 617-31.
38. Mathieu J, Zhou W, Xing Y, et al.Hypoxia-Inducible Factors Have Distinct and Stage-Specific Roles during Reprogramming of Human Cells to Pluripotency. Cell Stem Cell 2014; 14(5): 592-605.
39. Huebert RC, Rakela J. Cellular Therapy for Liver Disease. Mayo Clin Proc 2014; 89(3): 414-24.
40. Pfister O, Della Verde G, Liao R, et al.Regenerative therapy for cardiovascular disease. Transl Res 2014; 163(4): 307-20.
41. Nishikawa S-i, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008; 9(9): 725-9.
42. Hargus G, Cooper O, Deleidi M, et al.Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010; 107(36): 15921-6.
43. Yoshizato K, Tateno C. A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next? Expert Opin Drug Metab Toxicol 2013; 9(11): 1419-35.
44. Miura K, Okada Y, Aoi T, et al.Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009; 27(8): 743-5.
45. Polo JM, Liu S, Figueroa ME, et al.Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28(8): 848-55.
46. Bar-Nur O, Russ HA, Efrat S, et al.Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell 2011; 9(1): 17-23.
47. Vaskova E, Stekleneva A, Medvedev S, et al.“Epigenetic Memory” Phenomenon in Induced Pluripotent Stem Cells. Acta Naturae 2013; 5(4): 15-21.
48. Liu Z, Wen X, Wang H, et al.Molecular Imaging of Induced Pluripotent Stem Cell Immunogenicity with In vivo Development in Ischemic Myocardium. PLoS One 2013; 8(6): e66369.
49. Chen HF, Yu CY, Chen MJ, et al.Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and the derivatives. Cell Transplant 2013 [Epub ahead of print].
50. Dhodapkar KM, Feldman D, Matthews P, et al.Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci USA 2010; 107(19): 8718-23.
51. Lister R, Pelizzola M, Kida YS, et al.Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471(7336): 68-73.
52. Trowsdale J, Knight JC. Major Histocompatibility Complex Genomics and Human Disease. Annu Rev Genomics Hum Genet 2013; 14: 301-23.
53. Suárez-Álvarez B, Rodriguez RM, Calvanese V, et al.Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One 2010; 5(4): e10192.
54. Robertson NJ, Brook FA, Gardner RL, et al.Embryonic stem cellderived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci USA 2007; 104(52): 20920-5.
55. Fernandes E, Goold HD, Kissenpfennig A, et al.The role of direct presentation by donor dendritic cells in rejection of minor histocompatibility antigen-mismatched skin and hematopoietic cell grafts. Transplantation 2011; 91(2): 154-60.
56. Mölne J, Björquist P, Andersson K, et al.Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte-and cardiomyocyte-like cells. Transplantation 2008; 86(10): 1407-13.
57. Farrar CA, Kupiec-Weglinski JW, Sacks SH. The Innate Immune System and Transplantation. Cold Spring Harb Perspect Med 2013; 3(10): a015479.
58. Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol 2014; 26(2): 138-44.
59. Hanna J, Wernig M, Markoulaki S, et al.Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318(5858): 1920-3.
60. Boyd AS, Wood KJ. Characteristics of the early immune response following transplantation of mouse ES cell derived insulinproducing cell clusters. PLoS One 2010; 5(6): e10965.
61. van Sandwijk M, Bemelman F, Ten Berge I. Immunosuppressive drugs after solid organ transplantation. Neth J Med 2013; 71: 281-9.
62. Awe JP, Crespo AV, Li Y, et al.BAY11 enhances OCT4 synthetic mRNA expression in adult human skin cells. Stem Cell Res Ther 2013; 4(1): 15.
63. Waldmann H, Hilbrands R, Howie D, et al.Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest 2014; 124(4): 1439-45.
64. Pearl JI, Lee AS, Leveson-Gower DB, et al.Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011; 8(3): 309-17.
65. Haque R, Lei F, Xiong X, et al.Programming of regulatory T cells from pluripotent stem cells and prevention of autoimmunity. J Immunol 2012; 189(3): 1228-36.
66. Naji A, Rouas-Freiss N, Durrbach A, et al.Concise review: combining human leukocyte antigen g and mesenchymal stem cells for immunosuppressant biotherapy. Stem Cells 2013; 31(11): 2296-303.
67. Villa-Diaz L, Brown S, Liu Y, et al. Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates. Stem Cells 2012; 30(6): 1174-81.
68. Zhu S, Rezvani M, Harbell J, et al.Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature 2014; 508(7494): 93-7.
69. Müller LU, Milsom MD, Harris CE, et al.Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012; 119(23): 5449-57.
70. Guan X, Mack DL, Moreno CM, et al.Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery. Stem Cell Res 2014; 12(2): 467-80.
71. Tiscornia G, Vivas EL, Matalonga L, et al.Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Hum Mol Genet 2013; 22(4): 633-45.
72. Ryan SD, Dolatabadi N, Chan SF, et al.Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1 transcription. Cell 2013; 155(6): 1351-64.
73. Guo X, Disatnik M-H, Monbureau M, et al.Inhibition of mitochondrial fragmentation diminishes Huntington’s disease– associated neurodegeneration. J Clin Invest 2013; 123(12): 5371.
74. Briggs JA, Sun J, Shepherd J, et al.Integration‐Free Induced Pluripotent Stem Cells Model Genetic and Neural Developmental Features of Down Syndrome Etiology. Stem Cells 2013; 31(3): 467-78.
75. Mekhoubad S, Bock C, de Boer AS, et al.Erosion of dosage compensation impacts human iPSC disease modeling. Cell Stem Cell 2012; 10(5): 595-609.
76. Tulpule A, Kelley JM, Lensch MW, et al.Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 2013; 12(6): 727-36.